XORTX Therapeutics (XRTX) Total Current Liabilities (2020 - 2024)

XORTX Therapeutics' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $340928.0 for Q1 2024.

• Quarterly Total Current Liabilities changed N/A year-over-year to $340928.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $340928.0 (changed N/A YoY) and the FY2023 annual result came in at $294938.0, down 80.48% from the prior year.
• Total Current Liabilities was $340928.0 for Q1 2024 at XORTX Therapeutics, up from $294938.0 in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.5 million in Q4 2022 and bottomed at $294938.0 in Q4 2023.
• A 5-year average of $636106.4 and a median of $553757.0 in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 171.6% — and 2023, when it tumbled 80.47%.
• XORTX Therapeutics' Total Current Liabilities stood at $793297.9 in 2020, then retreated by 29.9% to $556127.8 in 2021, then surged by 171.6% to $1.5 million in 2022, then tumbled by 80.47% to $294938.0 in 2023, then grew by 15.59% to $340928.0 in 2024.
• Business Quant data shows XRTX's Total Current Liabilities at $340928.0 in Q1 2024, $294938.0 in Q4 2023, and $553757.0 in Q3 2023.